Viral hepatitis prevalence in patients with active and latent tuberculosis by Nooredinvand, HA et al.
8920 August 7, 2015|Volume 21|Issue 29|WJG|www.wjgnet.com
Submit a Manuscript: http://www.wjgnet.com/esps/
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
DOI: 10.3748/wjg.v21.i29.8920
World J Gastroenterol  2015 August 7; 21(29): 8920-8926
 ISSN 1007-9327 (print)  ISSN 2219-2840 (online)
© 2015 Baishideng Publishing Group Inc. All rights reserved.
ORIGINAL ARTICLE
Hesam Ahmadi Nooredinvand, Mahmoud Asgheddi, 
Mohammed Abdullah, Louise Campbell, Shahid A Khan, 
Hepatology and Gastroenterology Section, Division of Diabetes 
Endocrinology and Metabolism, Department of Medicine, Imperial 
College London, W2 1NY London, United Kingdom
David W Connell, Marie O’Donoghue, Melissa I Wickremasinghe, 
Ajit Lalvani, Onn Min Kon, Tuberculosis Service, St Mary’s 
Hospital, Imperial College Healthcare NHS Trust, W2 1NY 
London, United Kingdom
Shahid A Khan, Liver Unit, St Mary’s Hospital, Imperial 
College London, W2 1NY London, United Kingdom
Author contributions: All authors contributed to this work.
Supported by Grants from the Wellcome Trust; and the Higher 
Education Funding Council for England.
Conflict-of-interest statement: The authors declare no competing 
interest.
Open-Access: This article is an open-access article which was 
selected by an in-house editor and fully peer-reviewed by external 
reviewers. It is distributed in accordance with the Creative 
Commons Attribution Non Commercial (CC BY-NC 4.0) license, 
which permits others to distribute, remix, adapt, build upon this 
work non-commercially, and license their derivative works on 
different terms, provided the original work is properly cited and 
the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
Correspondence to: Shahid A Khan, BSc, PhD, FRCP, Liver 
Unit, St Mary’s Hospital, Imperial College London, 10th Floor 
QEQM Building, South Wharf Road, W2 1NY London, 
United Kingdom. shahid.khan@imperial.ac.uk
Telephone: +44-203-3126454
Fax: +44-207-4022796
Received: December 22, 2014
Peer-review started: December 23, 2014
First decision: January 27, 2015
Revised: February 23, 2015
Accepted: April 9, 2015
Article in press: April 9, 2015
Published online: August 7, 2015
Abstract
AIM: To assess the prevalence of hepatitis B virus 
(HBV) and hepatitis C virus (HCV) infection and asso-
ciation with drug induced liver injury (DILI) in patients 
undergoing anti-tuberculosis (TB) therapy.
METHODS: Four hundred and twenty nine patients 
with newly diagnosed TB - either active disease or 
latent infection - who were due to commence anti-
TB therapy between September 2008 and May 2011 
were included. These patients were prospectively 
tested for serological markers of HBV, HCV and human 
immunodeficiency virus (HIV) infections - hepatitis B core 
antigen (HBcAg), hepatitis B surface antigen (HBsAg), 
hepatitis B e antigen, IgG and IgM antibody to HBcAg 
(anti-HBc), HCV IgG antibody and HIV antibody using a 
combination of enzyme-linked immunosorbent assay, 
Western blot assay and polymerase chain reaction 
techniques. Patients were reviewed at least monthly 
during the TB treatment initiation phase. Liver function 
tests were measured prior to commencement of anti-
TB therapy and 2-4 wk later. Liver function tests were 
also performed at any time the patient had significant 
nausea, vomiting, rash, or felt non-specifically unwell. 
Fisher’s exact test was used to measure significance 
in comparisons of proportions between groups. A P  
value of less than 0.05 was considered statistically 
significant.
RESULTS: Of the 429 patients, 270 (62.9%) had 
active TB disease and 159 (37.1%) had latent TB 
infection. 61 (14.2%) patients had isolated anti-HBc 
positivity, 11 (2.6%) were also HBsAg positive and 7 
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(1.6%) were HCV-antibody positive. 16/270 patients 
with active TB disease compared to 2/159 patients 
with latent TB infection had markers of chronic viral 
hepatitis (HBsAg or HCV antibody positive; P  = 0.023). 
Similarly the proportion of HBsAg positive patients 
were significantly greater in the active vs  latent 
TB infection group (10/43 vs  1/29, P  = 0.04). The 
prevalence of chronic HBV or HCV was significantly 
higher than the estimated United Kingdom prevalence 
of 0.3% for each. We found no association between 
DILI and presence of serological markers of HBV or 
HCV. Three (5.3%) patients with serological markers of 
HBV or HCV infection had DILI compared to 25 (9.5%) 
patients without; P  = 0.04.
CONCLUSION: Viral hepatitis screening should be 
considered in TB patients. DILI risk was not increased 
in patients with HBV/HCV.
Key words: Epidemiology; Hepatitis B; Hepatitis C; 
Tuberculosis; Drug induced liver injury
© The Author(s) 2015. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Tuberculosis (TB) patients are not routinely 
tested for viral hepatitis in the United Kingdom. This is 
the first study from a European centre investigating the 
prevalence of hepatitis B virus (HBV) and hepatitis C virus 
(HCV) in patients with TB. We found that chronic HBV 
and HCV prevalence in TB patients were 9 and 5 times 
greater than the estimated United Kingdom prevalence 
respectively. We also found that a significantly greater 
proportion of patients with active TB had chronic 
Hepatitis B compared with patients with latent TB 
infection. In our study there was no association between 
drug induced liver injury risk and presence of serological 
markers of HBV/HCV.
Nooredinvand HA, Connell DW, Asgheddi M, Abdullah M, O’
Donoghue M, Campbell L, Wickremasinghe MI, Lalvani A, 
Kon OM, Khan SA. Viral hepatitis prevalence in patients with 
active and latent tuberculosis. World J Gastroenterol 2015; 
21(29): 8920-8926  Available from: URL: http://www.wjgnet.
com/1007-9327/full/v21/i29/8920.htm  DOI: http://dx.doi.
org/10.3748/wjg.v21.i29.8920
INTRODUCTION
Tuberculosis (TB) is the leading cause of death from a 
curable infectious disease; in 2010, 1.45 million people 
died from TB and there were 8.8 million incident 
cases[1]. In the United Kingdom, the incidence of TB 
has steadily increased over the past two decades[2]. 
7892 cases were reported in 2013, the majority in 
urban areas, with London accounting for 38% of those 
cases[2]. Over 80% of cases are non-United Kingdom 
born, and rates of TB in the non-United Kingdom born 
are approximately twenty-fold higher (86/100000) 
than those born in United Kingdom (4/100000)[2].
Standard four-drug anti-TB therapy for active 
disease (isoniazid, rifampicin, pyrazinamide and 
ethambutol) is associated with a range of significant 
side effects, the most serious of which is drug induced 
liver injury (DILI), which carries a mortality rate of 
up to 5%[3,4]. All anti-TB medications are potential 
causes of DILI[5]. The incidence of DILI from anti-TB 
treatment has been variably reported - between 2% 
and 28% - with a number of factors, including HLA 
phenotype and ethnicity, having been found to alter an 
individual’s risk for a hepatotoxic drug reaction[5,6]. The 
clinical presentation of DILI ranges from transient mild 
elevation of liver enzymes to fulminant liver failure, 
and a commonly used definition of DILI is an increase 
in serum alanine transaminase (ALT) greater than 3 or 
5 times the upper limit of normal (ULN) with or without 
symptoms of acute hepatitis respectively[4].
The World Health Organization (WHO) estimates 
approximately 240 million people worldwide are 
chronically infected with hepatitis B virus (HBV)[7]. 
Areas of high prevalence are similar to the global 
TB epidemiological “hotspots” and include sub-
Saharan Africa and South Asia, where the prevalence 
is estimated to be between 8 and 20%[8]. The WHO 
estimate 3% of the World’s population are infected with 
hepatitis C virus (HCV), with 170 million being chronic 
carriers[9]. European countries report a prevalence of 
HCV in the general population of between 0.5%-2% 
and global areas of high prevalence again include 
Africa, particularly Egypt, and Asia[9]. In 2011 it was 
estimated that around 216000 individuals were the 
United Kingdom are chronically infected with HCV[10], 
and the HPA and WHO estimate the United Kingdom 
prevalence of chronic HBV infection to be similar to 
this, at 0.3%. Chronic infection with HBV and/or HCV 
can cause progressive liver fibrosis and cirrhosis, 
liver failure and liver cancer. Effective therapies exist 
for both these viruses if they are diagnosed before 
advanced liver disease occurs, and early detection and 
treatment is important in minimising the health burden 
associated with chronic HBV and HCV. However, both 
these viruses are relatively asymptomatic and hence 
international liver associations recommend screening 
for HBV and HCV in high risk groups[11,12]. 
Several studies report an increased prevalence of 
viral hepatitis infection in TB patients[14-17] (Table 1). 
However, none of these studies have been performed 
in a European setting, so their applicability to the 
United Kingdom is not known. Although results are not 
universal, a number of international studies suggest 
that co-existing viral hepatitis may be a significant risk 
factor for DILI[13,18-22]. No studies on the prevalence of 
viral hepatitis in patients undergoing anti-TB therapy 
and the risk they add to DILI have been carried out in 
the United Kingdom or Europe, which have seen an 
increase in TB cases over recent years.
Table 1  Prevalence of hepatitis B virus and hepatitis C virus infection in tuberculosis patients in other studies  n  (%)
8922 August 7, 2015|Volume 21|Issue 29|WJG|www.wjgnet.com
United Kingdom patients infected with TB are 
offered human immunodeficiency virus (HIV) scree-
ning[23] due to an increased prevalence of co-infection, 
but viral hepatitis screening is not routinely offered and 
might be of value if the background prevalence of viral 
hepatitis is significant in patients with TB infection. 
London is a multicultural city with a significant number 
of immigrants from high endemic TB countries, 
suggesting that the prevalence of viral hepatitis 
infection may be higher than suspected.
MATERIALS AND METHODS
Recruitment
We recruited patients with newly diagnosed TB - either 
active disease or latent infection - at St. Mary’s Hospital, 
Imperial College Healthcare NHS Trust, London, who 
were due to commence standard anti-TB therapy for 
either stages of the infection between September 
2008 and May 2011. The inclusion criteria were: newly 
diagnosed TB (active or latent); 18 years of age or 
above; ability to give informed consent; and no known 
history of chronic liver disease, viral hepatitis or HIV. 
No patients were immunosuppressed. Research ethics 
approval was obtained (No. 10/H0709/44).
Clinical phenotyping
TB infection was confirmed using the standard protocols 
in our clinic. Active TB infection was defined by 
clinical and radiological characteristics of symptomatic 
TB infection, with or without confirmatory culture 
information. If culture negative, then the patient 
was deemed to have had active TB if they made a 
satisfactory response to anti-tuberculosis therapy.
Latent TB infection was defined as an asym-
ptomatic patient without radiographic evidence of 
active TB disease, and with a positive tuberculin skin 
test read at 48-72 h by an experienced nurse (defined 
as > 5 mm induration if not BCG vaccinated or ≥ 15 
mm if BCG vaccinated), subsequently confirmed with a 
positive interferon gamma release assay [either T.Spot.
TB (Oxford Immunotec, Oxford, United Kingdom), 
or Quantiferon Gold-in-Tube (Cellestis Ltd, Victoria, 
Australia)].
Drug treatment
For active disease, standard anti-tuberculous therapy 
in our clinic was rifampicin 600 mg/d (R), Isoniazid 
300 mg/d (H), Pyrazinamide 25 mg/kg per day (Z) 
(these three jointly given as Rifater with the number 
of tablets dependent on weight; if the weight was 
sufficiently low, then the drugs were given separately 
as per guidelines[23]), and Ethambutol 15 mg/kg 
per day (E) for 2 mo; followed by continuation 
rifampicin and isoniazid for a further 4 mo [8 mo if 
central nervous system (CNS) involvement]. Treating 
clinicians had the option to extend the initiation phase 
to 3 mo if the patient was persistently smear positive 
after one month of therapy and could extend the 
total duration of therapy if they felt the initial burden 
disease was high, on a case by case basis. Adjuvant 
steroid therapy was used in patients with pericardial or 
CNS disease, as per national guidelines[23] and weekly 
pyridoxine 50mg orally was administered to all cases. 
Drug resistant cases were treated according to culture 
results as per national guidelines[23].
For latent infection, patients were treated with 3 
mo of Rifampicin 600mg daily (R) and Isoniazid 300 
mg daily (H) (jointly given as Rifinah-300, two tablets 
daily), in keeping with standard United Kingdom 
practice.
Data collection
Patients’ demographic, serological and clinical data 
were collected following informed consent, from the 
London TB register, hospital clinical databases and 
clinical notes. Demographic information collected 
included age, gender and ethnicity. In addition to 
biochemical liver function tests, the following serological 
results were also collected: HIV antibody, hepatitis 
B core antigen (HBcAg), hepatitis B surface antigen 
(HBsAg), hepatitis B e antigen (HBeAg), IgG and IgM 
antibody to HBcAg (anti-HBc) and HCV IgG antibody 
(anti-HCV).
As per standard clinical protocol, patients were 
reviewed at least monthly during the TB treatment 
initiation phase. Liver function tests, including alanine 
transaminase (ALT) levels, were measured prior to 
commencement of anti-TB therapy and again 2-4 
wk later. An ALT level of 40 IU/mL was taken as the 
upper limit of normal (ULN). DILI was defined as an 
ALT of greater than 80IU/ml (2 × ULN), as defined by 
the Council for International Organisation of Medical 
Sciences (CIOM) DILI diagnostic scale[24] with no 
other apparent cause for abnormal liver biochemistry. 
Severe DILI was defined at an ALT of 5 × ULN. Liver 
Study (country) Study population Number of patients HBsAg HBsAg or anti-HBc Anti-HCV
Kuniholm et al[14] (Georgia) All active TB patients 300    13 (4.3) 27 (9)   36 (12)
Blal et al[15] (Brazil) All active TB patients 209      6 (2.8)      56 (26.8) -
Sirinak et al[16] (Thailand) HIV infected active TB patients 849 70 (9) - 237 (31)
Aires et al[17] (Brazil) All active TB patients 402    13 (3.2)    103 (25.6) -
HBsAg: Hepatitis B surface antigen; HCV: Hepatitis C virus; HBc: Hepatitis B core; TB: Tuberculosis.
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function tests (LFTs) were performed at any time the 
patient had significant nausea, vomiting, rash, or felt 
non-specifically unwell.
HIV, HBV and HCV serological tests were performed 
at St Mary’s hospital pathology department. Enzyme-
linked immunosorbent assay (ELISA) was used for 
detection of anti-HIV antibodies and confirmed by 
Western blot assay. Screening for HBV and HCV 
was conducted using second generation ELISA and 
confirmatory tests for HBsAg or HCV positive results 
included polymerase chain reaction techniques. Data 
were analysed using Prism 5 (GraphPad Software 
Inc.). Fisher’s exact test was used to measure sig-
nificance in comparisons of proportions between 
groups. A P value of less than 0.05 was considered 
statistically significant.
RESULTS
Demographics
A total of 487 patients were recruited. 58 patients 
were excluded due to absent results or loss to follow 
up. Of the remaining 429 patients, 270 (62.9%) 
patients had active TB disease and 159 (37.1%) had 
latent TB infection. The mean age was 46.4 years and 
51.3% of patients were male. The majority of patients 
were from the Indian Subcontinent and Sub Saharan 
Africa, together accounting for 59.7% of patients. 7.5% 
of patients were White British (Table 2).
Prevalence of HCV/HBV markers
Of 429 patients screened, 79 (18.4%) had positive 
serological markers for HBV or HCV infection. 61 
(14.2%) had isolated anti-HBc antibody only; 11 
(2.6%) were also HBsAg positive and 7 (1.6%) were 
positive for HCV IgG antibody. No patients had HBV/
HCV co-infection (Table 2). All patients positive for 
HBsAg and HCV Antibody were previously unknown to 
have a history of viral hepatitis.
Active TB disease vs latent TB infection
A similar proportion of patients in both groups had 
serological markers for HBV or HCV infection (49/270 
active TB disease patients vs 30/159 latent TB infection 
patients; P = 0.9, Fisher’s exact test) (Table 3).
However, there was a significant difference between 
these groups with respect to chronic viral hepatitis: 
16/270 patients with active TB disease compared to 
2/159 patients with latent TB infection had markers of 
chronic viral hepatitis (HBsAg or HCV antibody positive; 
P = 0.023, Fisher’s exact test). Similarly, while there 
was no difference between the groups with respect 
to anti-HBc antibody positivity (43/270 in active TB 
disease group vs 29/159 in latent TB infection group; 
P = 0.59, Fisher’s exact test), the proportion of this 
group whose HBsAg was positive was significantly 
greater in the active TB patient group (10/43 in active 
TB patients vs 1/29 in latent TB infection group; P = 
0.04, Fisher’s exact test).
A greater proportion of active TB disease patients 
were HCV seropositive compared to latent TB infection 
patients although this difference was not significant 
(6/270 active TB disease patients vs 1/159 latent TB 
infection patients; P = 0.27, Fisher’s exact test).
Viral hepatitis and HIV co-infection
Fifteen patients were already known to be HIV positive 
and a further 260 patients consented to HIV screening 
(245 active TB disease, 30 latent TB infection). Eleven 
patients were newly diagnosed with HIV meaning that, 
of the 275 patients, 26 (9.5%) were infected with 
HIV. Six (23.1%) of the HIV positive patients were co-
Characteristic Patients
Total HBV/HCV Negative HBsAg Isolated Anti-HBc (IgG) HCV (IgG)
   Female 209 (48.7) 173 (40.3)   4 (0.9) 31 (7.2) 1 (0.2)
   Male 220 (51.3) 177 (41.3)   7 (1.6) 30 (7.0) 6 (1.4)
Age (yr)
   18-35 155 (36.1) 132 (30.8)   0 (0.0) 21 (4.9) 2 (0.5)
   36-53 133 (31.0) 106 (24.7)   7 (1.6) 16 (3.7) 4 (0.9)
   54-71   88 (20.5)   67 (15.6)   3 (0.7) 17 (4.0) 1 (0.2)
   72-90   51 (11.9)   43 (10.0)   1 (0.2)   7 (1.6) 0 (0.0)
   > 90   2 (0.5)   2 (0.5)   0 (0.0)   0 (0.0) 0 (0.0)
Ethinicity
   Indian Subcontinent 152 (35.4) 132 (30.8)   1 (0.2) 18 (4.2) 1 (0.2)
   Black African (Sub Saharan) 104 (24.2)   73 (17.0)   6 (1.4) 23 (5.4) 2 (0.5)
   Black Caribbean 21 (4.9) 17 (4.0)   0 (0.0)   4 (0.9) 0 (0.0)
   North African 25 (5.8) 20 (4.7)   0 (0.0)   5 (1.2) 0 (0.0)
   South East Asia 34 (7.9) 26 (6.1)   3 (0.7)   5 (1.2) 0 (0.0)
   White all other (European/American/Australian)   46 (10.7) 38 (8.9)     1 (0.02)   5 (1.2) 2 (0.5)
   White South American 15 (3.5) 15 (3.5)   0 (0.0)   0 (0.0) 0 (0.0)
   White UK 32 (7.5) 29 (6.8)   0 (0.0)     1 (0.02) 2 (0.5)
Total 429 350 (81.6) 11 (2.6)   61 (14.2) 7 (1.6)
HBsAg: Hepatitis B surface antigen; HBV: Hepatitis B virus; HCV: Hepatitis C virus; HBc: Hepatitis B core.
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Table 3  Prevalence of hepatitis B virus and hepatitis C virus 
infection in active TB disease vs latent tuberculosis infection 
patients  n  (%)
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infected with HBV or HCV (P = 0.26, Fisher’s exact test).
Pre-treatment ALT Levels
Pre-treatment ALT levels were available in 399 patients, 
71 of whom were HCV or anti-HBc positive (including 
those also positive for HBsAg). Fourteen (19.7%) of 
these patients had ALT levels of greater than 40 IU/mL 
compared to 61 (18.6%) patients negative for markers 
of HBV or HCV (P = 0.87, Fisher’s exact test). 13 (3.3%) 
patients had ALTs of greater than 2 × ULN (> 80 IU/
mL), 3 of whom had ALTs of greater than 5 × ULN (> 
200 IU/mL). All of these patients were negative for all 
markers for HBV and HCV.
Post-treatment ALT Levels
Post-treatment ALTs were documented in 396 patients, 
72 of whom were HCV or anti-HBc positive (including 
those also positive for HBsAg). 16 (22.2%) of these 
patients had ALT elevation > 40 IU/mL compared to 89 
(27.5%) patients negative for markers of HBV or HCV 
(P = 0.31, Fisher’s exact test). Six (8.3%) anti-HBc or 
HCV positive patients had ALT > 80 IU/mL compared 
to 33 (10.2%) patients without serological evidence of 
HBV or HCV (P = 0.83, Fisher’s exact test). Of the 13 
patients with ALT > 200 IU/mL, only one was positive 
for HBV or HCV serological markers (P = 0.48, Fisher’s 
exact test).
ALT levels post-treatment following normal pre-
treatment levels
Three hundred and twenty patients had normal (< 
40 IU/mL) pre-treatment ALTs and also had follow-up 
LFTs; of these, 57 were positive for serological markers 
HBV or HCV. ALT elevation of greater than 80 IU/mL 
was seen in 3 (5.3%) patients with positive HBV or 
HCV serological markers, compared to 25 (9.5%) 
patients negative for serological markers HBV/HCV 
(P = 0.44, Fisher’s exact test). Twelve patients had 
ALT > 200 IU/mL of whom only one had serological 
evidence of HBV/HCV (P = 0.70, Fisher’s exact test). 
Five patients required interruption of treatment due 
to significantly elevated LFTs, none of whom had 
serological evidence of HBV/HCV. Overall, 13 (46.4%) 
of the 28 patients with DILI were above the age of 50 
and 14 (50%) were male.
DISCUSSION
This is the first study from a European centre to 
investigate the prevalence of HBV and HCV in patients 
with TB. We found that 18.4% of newly diagnosed 
TB patients at a central London teaching hospital had 
markers of HBV or HCV; 2.6% of patients were HBsAg 
positive and 1.6% were anti-HCV Ab positive. All these 
diagnoses were new, and led to specialist referral 
with the aim of preventing long-term complications of 
chronic viral hepatitis.
Our study found that chronic HBV prevalence 
in TB patients was almost 9 times greater than the 
estimated overall United Kingdom prevalence. Similarly, 
the prevalence of HCV amongst TB patients in our 
study was over 5 times greater than the estimated 
United Kingdom prevalence of HCV. The majority of 
infected patients were of Indian Subcontinent or Black 
African origin, and our distribution of ethnicities was 
representative of London’s multi-racial TB population[25].
A recent study by Uddin and colleagues looked 
at the prevalence of HBV and HCV in South Asian 
immigrants in England attending community centres[26]. 
4998 individuals were screened and HBsAg or anti-
HCV Ab was present in 1.2% and 1.6% of patients 
respectively, again higher than the national estimated 
prevalence. This may be partially explained by the 
older demographic screened in this study - attending 
mosques and temples - who are more likely to have 
been born and raised in South Asia and hence would 
be at a greater risk of acquiring infection with HBV/HCV 
at younger ages. The prevalence of chronic hepatitis 
B in our study was more than twice that found in the 
study by Uddin et al[26], reflecting the wider ethnic 
background to our population, and suggesting that 
screening for HBV and HCV may be more effective in 
health care settings which might capture a wider range 
of infected individuals.
Although HIV and HBV/HCV have similar risk factors, 
we found no significant association between these 
infections in our cohort of TB patients, suggesting that 
HIV seropositivity alone would not identify patients with 
unknown HBV/HCV.
Of note, a significantly greater proportion of pa-
tients with active TB had chronic Hepatitis B compared 
with patients with latent TB infection. The proportion 
of patients in the latent and active groups positive for 
anti-HBc did not differ, suggesting that whilst both 
groups had equal exposure to the virus, the group 
with active TB were more likely to fail to clear virus 
and remain sAg positive. This could be attributable 
to the relatively small number of latent TB patients 
in the study; alternatively, there may be shared pa-
HBV/HCV infection Patients P  value (Fisher’s 
exact test)
Active Latent
HBsAg/HCV Ab both 
negative
 221 (81.9)  129 (81.1) 0.9
HBsAg or HCV Ab positive    49 (18.1)    30 (18.9)
HCV (IgG) positive    6 (2.2)    1 (0.6) 0.27
Anti-HBc (IgG) positive    43 (12.2)    29 (17.6) 0.59
Of these: HBsAg positive > 10 (23.2) > 1 (3.4) > 0.04
HBsAg: Hepatitis B surface antigen; HCV: Hepatitis C virus; HBc: 
Hepatitis B core.
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thways of immune control, perhaps involving MHC 
I-restricted CD8 T cells important in both viral[27] and 
mycobacterial[28] control, which could link immune 
dysregulation in both Hepatitis B viral infection and M. 
tuberculosis infection.
It is relevant to note that, on further follow-up, 
none of the patients with HBsAg and/or Anti HCV 
positivity had cirrhosis, as chronic liver disease itself is 
a potential risk factor for acquiring TB.
Different studies have used varying definitions 
of hepatotoxicity; our study employed a range of 
thresholds, including one which is lower than the 
ATS guidelines on hepatotoxicity[29], with the aim 
of providing a more comprehensive analysis of the 
derangement in liver function that might occur in this 
population. Our study followed a standard protocol 
whereby LFTs were measured pre-treatment and 2-4 
wk after treatment. Further LFTs were only measured 
if the patient had abnormal levels at week 2-4 or 
developed symptoms; it is therefore possible that 
patients developing asymptomatic DILI after 2-4 wk 
of treatment may have been missed, although this is 
not common[29]. As with a number of other studies, we 
found no association between HBV/HCV seropositivity 
and DILI at both a lower and a higher threshold for 
diagnosis[5,16,30]; suggesting that anti-TB medication 
can generally be safely administered to those infected 
with HBV/HCV in settings similar to ours, provided 
liver function is regularly monitored. Although DILI 
tends to occur early in the course of anti-TB therapy, 
the prevalence of DILI in our study may potentially be 
underestimated as follow-up liver function tests were 
only checked once, unless clinically indicated.
It is also important to note that over 14% of 
patients undergoing anti-TB treatment were positive 
for anti-HBc. Without prophylactic anti-viral therapy, 
these patients are at risk of HBV reactivation and 
liver failure if they are immunosuppressed or undergo 
immunomodulatory therapy or chemotherapy in the 
future.
Without early detection and appropriate manage-
ment, chronic infection with HBV or HCV can lead 
to cirrhosis, liver failure and liver cancer. The Health 
Protection Agency (United Kingdom) advises HCV 
screening in intravenous drug users (IVDU) and men 
who have sex with men[10] and the ATS recommends 
viral hepatitis screening in TB patients with risk factors 
such as IVDU, those born in endemic areas and in HIV 
positive individuals[29]. As the majority of TB patients in 
the United Kingdom are immigrants from areas of the 
world where viral hepatitis is endemic, this strengthens 
the clinical utility of screening TB patients for viral 
hepatitis.
The high prevalence of HBV and HCV in our cohort 
likely reflects the relatively high prevalence of these 
viruses in their countries of origin. The relevance of 
our findings is that screening recommendations for 
HBV for individuals born in high prevalence areas, such 
as the American Association for the Study of Liver 
Diseases guidelines on chronic HBV, should be carried 
out in TB patients and extended to HCV screening. 
We propose that screening for hepatitis B and 
C be considered in TB patients (particularly those 
with active TB) in multicultural cities of the United 
Kingdom with high rates of patients originating from 
areas of the world where HBV and HCV are relatively 
more highly prevalent. Further studies to identify TB 
patients at highest risk of HBV/HCV co-infection, to 
investigate links between active TB and Hepatitis B, 
and to investigate the health economics of screening 
are warranted.
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Background
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